Kimberly Ha notes that many big pharma companies are partnering with academic institutions and that oncology, followed by neurology is one of the hottest areas in acquisitions
Global Cancer Consortium
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Editor’s Note November 29, 2011
OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. […]
EpiCept’s Ceplene Product Receives Marketing Auth. by European Commission
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
PLC Medical Systems Uses Revenue in the EU to Fund Phase III Development in the US
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
